Global Allergy Diagnostics And Treatment Market Size By Type (Assay Kits, Consumables), By Application (Food Allergen, Inhaled Allergen), By Region, And Segment Forecasts, 2023 to 2032

The Global Allergy Diagnostics and Treatment Market was valued at USD 31.4 billion in 2023 and is projected to reach USD 56.7 billion by 2031, growing at a CAGR of 7.9% during the forecast period of 2023 to 2031. This growth is driven by the increasing prevalence of allergic conditions worldwide, heightened awareness regarding early allergy diagnosis, and significant advancements in immunotherapy and diagnostic technologies. Rising pollution levels, changing lifestyles, and greater healthcare access are further accelerating the adoption of allergy testing and personalized treatment regimens across diverse patient populations.

Drivers:

1. Rising Prevalence of Allergic Diseases:

Chronic allergic conditions such as asthma, allergic rhinitis, atopic dermatitis, and food allergies are on the rise globally. This has led to an increased demand for both diagnostic testing and effective long-term treatment options, especially in urban populations.

2. Technological Advancements in Diagnostics:

Innovations such as component-resolved diagnostics (CRD), multiplex assays, and point-of-care testing are enhancing the accuracy and efficiency of allergy detection. These advancements allow for early intervention and more personalized treatment plans.

3. Growing Adoption of Immunotherapy:

Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are gaining prominence as disease-modifying treatments, providing long-term relief and reducing dependence on symptomatic drugs. Increased clinician and patient awareness is expanding the adoption of these therapies.

Restraints:

1. High Costs of Advanced Allergy Testing:

Despite their diagnostic accuracy, advanced molecular tests and CRD-based platforms can be costly, posing accessibility challenges in low- and middle-income countries. This can delay diagnosis and treatment in economically weaker sections.

2. Limited Awareness in Emerging Economies:

A lack of widespread public and professional awareness about allergic conditions and treatment options in emerging markets may hinder growth. Underdiagnosis and misdiagnosis continue to be major concerns.

Opportunity:

1. Expansion of Allergy Clinics in Developing Regions:

As healthcare infrastructure improves across Asia-Pacific, Africa, and Latin America, the establishment of specialized allergy centers is creating new opportunities for market penetration and revenue growth.

2. Development of Non-Invasive and Home-Based Testing Kits:

The emergence of home-testing kits and non-invasive sampling technologies is enhancing patient convenience and increasing diagnosis rates. These innovations are expected to significantly drive the market in the coming years.

Market by System Type Insights:

Based on system type, the In Vivo Allergy Testing segment dominated the market in 2023. Techniques such as skin prick testing (SPT) and intradermal testing continue to be widely used due to their affordability, rapid results, and diagnostic reliability. However, the In Vitro Testing segment is projected to witness the fastest growth due to the rising demand for high-precision, lab-based diagnostics and multiplex testing capabilities.

Market by End-use Insights:

In 2023, the Hospitals and Diagnostic Laboratories segment accounted for the largest revenue share, owing to the availability of comprehensive testing facilities and a high influx of patients with complex allergic conditions. Meanwhile, the Homecare and Pharmacies segment is rapidly emerging due to the growing popularity of over-the-counter allergy treatments and self-management kits.

Market by Regional Insights:

North America held the largest market share in 2023, driven by a high prevalence of allergic diseases, robust healthcare infrastructure, and strong reimbursement frameworks. However, the Asia-Pacific region is projected to exhibit the highest growth rate through 2031, fueled by increasing healthcare spending, urbanization, and a growing middle-class population with access to private healthcare services.

Competitive Scenario:

Key players in the Global Allergy Diagnostics and Treatment Market include Thermo Fisher Scientific Inc., Danaher Corporation, Stallergenes Greer, Eurofins Scientific, Siemens Healthineers, BioMérieux, Omega Diagnostics, and Lincoln Diagnostics. These companies are focusing on expanding their product portfolios, leveraging AI for diagnostics, and engaging in strategic mergers and acquisitions to maintain competitive advantage.

Scope of Work – Global Allergy Diagnostics and Treatment Market

Key Market Developments:

2023: Thermo Fisher Scientific launched a multiplex allergy testing panel capable of detecting over 300 allergens from a single blood sample.

2024: Stallergenes Greer entered a strategic collaboration with digital health providers to integrate allergy diagnostics into telehealth platforms.

2025: Danaher Corporation acquired a regional allergy diagnostics startup to expand its presence in Asia-Pacific and enhance its CRD offerings.

FAQs:

1) What is the current market size of the Global Allergy Diagnostics and Treatment Market?

The market was valued at USD 31.4 billion in 2023.

2) What is the major growth driver of the Global Allergy Diagnostics and Treatment Market?

The increasing prevalence of allergic diseases and advancements in allergy diagnostics are key growth drivers.

3) Which is the largest region during the forecast period in the Global Allergy Diagnostics and Treatment Market?

North America currently leads, but Asia-Pacific is expected to register the highest growth rate through 2031.

4) Which segment accounted for the largest market share in the Global Allergy Diagnostics and Treatment Market?

The Hospitals and Diagnostic Laboratories segment held the largest share in 2023.

5) Who are the key market players in the Global Allergy Diagnostics and Treatment Market?

Key players include Thermo Fisher Scientific Inc., Danaher Corporation, Stallergenes Greer, Eurofins Scientific, and Siemens Healthineers.